ARREST - A Phase I Study of SABR for Poly-metastatic Disease

Status Active, not recruiting

Clinical Trial Summary

Stereotactic ablative radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small areas in the body. This new technique can potentially allow radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. This improvement could help by reducing side effects overall (through radiation exposure to a smaller area of the body over a shorter time period), and by improving the chance of controlling the cancer by more precisely treating the cancer and by giving higher doses of radiation. SABR is considered a standard treatment for some lung cancers, and selected cancers that have spread to the brain. Ongoing studies are evaluating the use of SABR for treating people with up to 10 sites of cancer in the body, but its safety and value for treating patients with poly-metastatic cancer (more than 10 sites of cancer) is not yet known. The purpose of this study is to determine the safety of using SABR to treat people with poly-metastatic disease. To our knowledge, this is the first time that SABR will be tested in people who have poly-metastatic disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04530513
Study type	Interventional
Source	Lawson Health Research Institute
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	November 17, 2020
Completion date	June 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Recruiting	`NCT05798611` - Study of ART0380 in Patients With Biologically Selected Solid Tumors	Phase 2
Not yet recruiting	`NCT04931420` - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels	Phase 2
Recruiting	`NCT05566574` - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Withdrawn	`NCT00005030` - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver	Phase 1
Recruiting	`NCT05525858` - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting	`NCT04085029` - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Not yet recruiting	`NCT05981170` - Rurality Adapted Physical Activity Sport Health
Not yet recruiting	`NCT03058809` - Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood	Phase 1/Phase 2
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Terminated	`NCT00918645` - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis	N/A
Completed	`NCT01302808` - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	Phase 1
Withdrawn	`NCT00769990` - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases	Phase 1/Phase 2
Completed	`NCT00795678` - Chemotherapeutic Agents in Brain/Breast	N/A
Completed	`NCT00557102` - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung	Phase 2
Recruiting	`NCT00398437` - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer	N/A